-
2023-508076-11-00
5
2025-04-01
Colon cancer staged T3-4 and/or nodal positive by CT and/or MRI scan w
-
2023-503730-45-00
4
2025-03-21
Kearns-Sayre-Syndrom
-
2024-514594-21-00
5
2025-03-13
Heterozygous Familial Hypercholesterolemia
-
2023-508845-41-00
5
2025-03-11
Active juvenile idiopathic arthritis subtypes enthesitis-related arthr
-
2023-507754-33-00
4
2025-02-19
steroid-refractory chronic Graft-versus-Host-Disease
-
2024-514306-31-00
5
2025-02-13
Pyoderma gangrenosum
-
2023-505320-54-00
4
2025-01-30
Multiple System Atrophy
-
2023-505077-32-00
5
2025-01-28
Locally-advanced or metastatic non-squamous non-small cell lung cancer
-
2024-513852-13-00
5
2025-01-20
KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Col
-
2024-510805-27-00
5
2025-01-09
Sickle Cell Disease and Thalassaemia
-
2024-513420-41-00
10
2025-01-09
prematurity in neonates
-
2024-511188-26-00
5
2024-12-20
Relapsed/refractory multiple myeloma in patients who have received 1 t
-
2023-508813-18-00
4
2024-12-18
Refractory Focal Onset Epilepsy
-
2023-504022-19-01
5
2024-12-13
Polymyositis or dermatomyositis according to 2017 EULAR / ACR classifi
-
2023-510380-34-00
4
2024-12-10
Diffuse cutaneous systemic sclerosis (dcSSc)
-
2023-508191-11-00
5
2024-11-28
Systemic lupus erythematosus (SLE)
-
2024-512279-10-00
5
2024-11-25
Triple Negative Breast Cancer
-
2024-513009-30-00
4
2024-11-21
Moderate to Severe Crohn’s Disease
-
2023-509292-17-00
4
2024-11-08
primary high-risk lobular breast cancer
-
2023-509912-27-00
5
2024-11-07
Metabolic Dysfunction-Associated Steatotic Liver Disease(MASH) / Nonal
-
2023-510395-31-00
5
2024-10-30
Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Compensat
-
2023-504724-25-00
5
2024-10-16
Primary Myelofibrosis
-
2023-508787-29-00
4
2024-10-10
Triple-negative early breast cancer with low risk for recurrence
-
2023-506613-22-00
5
2024-09-25
coronary artery disease